Axi-Cel Provides Sustained Response in High-Risk Large B-cel

Patients with high-risk large B-cell lymphoma experienced durable responses when treated with first-line axicabtagene ciloleucel, according to results from the phase 2 ZUMA-12 trial.

Related Keywords

, Julio Chavez , Lymphoma Section , Malignant Hematology , Moffitt Cancer Center , Axi Cel , Zuma 12 Trial , High Risk Largeb Cell Lymphoma , Yescarta , Ash Annual Meeting ,